home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Epizyme, Inc. - Common Stock (NQ:EPZM)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 11, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Epizyme, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Epizyme Raises $85M Via Equity Issued At 21% Discount ↗

January 27, 2022

Epizyme Inc (NASDAQ: EPZM) has priced its underwritten public offering of 56.7 million shares at

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 27, 2022

Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) stock increased by 28.7% to $2.24 during Thursday's pre-market session. The company's market cap stands at $31.4...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

January 27, 2022

Good morning, trader! We're starting off the day with an overview of the biggest pre-market stock movers to watch on Thursday!

Via InvestorPlace

26 Stocks Moving in Thursday's Pre-Market Session ↗

January 27, 2022

Gainers The National Security Group, Inc. (NASDAQ: NSEC) rose 63.7% to $15.10 in pre-market trading after VR Insurance Holdings announced acquisition of The National...

Via Benzinga

Epizyme Announces Pricing of Public Offering of Common Stock

January 27, 2022

From Epizyme, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 26, 2022

Gainers Reneo Pharmaceuticals (NASDAQ:RPHM

Via Benzinga

Epizyme Announces Proposed Public Offering of Common Stock

January 26, 2022

From Epizyme, Inc.

Via Business Wire

Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates

January 10, 2022

From Epizyme, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

January 05, 2022

Before 10 am on Wednesday, 99 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sea (NYSE:SE) was the largest firm by market cap to set a...

Via Benzinga

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

December 12, 2021

From Epizyme, Inc.

Via Business Wire

Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

December 11, 2021

From Epizyme, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 10, 2021

Gainers Quoin Pharmaceuticals (NASDAQ:

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

December 02, 2021

From Epizyme, Inc.

Via Business Wire

Epizyme Announces Updates to Its Board of Directors

November 18, 2021

From Epizyme, Inc.

Via Business Wire

Epizyme to Participate in Jefferies London Healthcare Conference

November 12, 2021

From Epizyme, Inc.

Via Business Wire

Epizyme's Return On Capital Employed Insights ↗

November 10, 2021

Benzinga Pro data, Epizyme (NASDAQ:EPZM) reported Q3 sales of $5.20 million. Earnings fell to a loss of $64.16 million, resulting in a 10.09% decrease from last quarter. In Q2,...

Via Benzinga

Epizyme, inc (EPZM) Q3 2021 Earnings Call Transcript ↗

November 09, 2021

EPZM earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update

November 09, 2021

From Epizyme, Inc.

Via Business Wire

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 05, 2021

From Epizyme, Inc.

Via Business Wire

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414

November 04, 2021

From Epizyme, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

Epizyme Announces Date of Third Quarter 2021 Financial Results

November 02, 2021

From Epizyme, Inc.

Via Business Wire

Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making

November 01, 2021

From Epizyme, Inc.

Via Business Wire

Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 07, 2021

From Epizyme, Inc.

Via Business Wire

Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress

September 14, 2021

From Epizyme, Inc.

Via Business Wire

Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 20, 2021

From Epizyme, Inc.

Via Business Wire

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗

August 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com